Dalbavancin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dalbavancin
Dalbavancin.png
Clinical data
Legal status
?
Routes Intravenous
Identifiers
CAS number 171500-79-1 YesY
ATC code J01XA04
PubChem CID 16134410
ChemSpider 23340937 N
UNII 808UI9MS5K N
ChEMBL CHEMBL527063 N
Chemical data
Formula C88H100Cl2N10O28 
Mol. mass 1755.634 g/mol
 N (what is this?)  (verify)

Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[1]

Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.[2]

It possesses in vitro activity against a variety of Gram-positive pathogens[3][4] including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE).[5] It is a once-weekly, two-dose antibiotic, the rights to which Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[6]

The Food and Drug Administration approved dalbavancin in May 2014 for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria such as Staphylococcus aureus including methicillin-susceptible and methicillin-resistant strains of Streptococcus pyogenes, in intravenous dosage form.[7]

Clinical progress[edit]

Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the FDA said more data were needed before approval.[6] On September 9, 2008, Pfizer announced it will withdraw all marketing applications to conduct another phase-III clinical trial.[8] Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs.[9] Preliminary results in 2012 were promising.[10]

About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin.[11]

In May 2014, dalbavancin was approved by the FDA for use in the US for ABSSSIs, including MRSA and Streptococcus pyogenes infections.

References[edit]